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Blood pressure (BP) is a heritable risk factor for cardiovascular disease. To investigate genetic associations with systolic BP (SBP), diastolic
BP (DBP), mean arterial pressure (MAP), and pulse pressure (PP), we genotyped ~50,000 SNPs in up to 87,736 individuals of European
ancestry and combined these in a meta-analysis. We replicated findings in an independent set of 68,368 individuals of European
ancestry. Our analyses identified 11 previously undescribed associations in independent loci containing 31 genes including PDE1A,
HLA-DQB1, CDK6, PRKAG2, VCL, H19, NUCB2, RELA, HOXC@ complex, FBN1, and NFAT5 at the Bonferroni-corrected array-wide signif-
icance threshold (p < 6 3 107) and confirmed 27 previously reported associations. Bioinformatic analysis of the 11 loci provided
support for a putative role in hypertension of several genes, such as CDK6 and NUCB2. Analysis of potential pharmacological targets
in databases of small molecules showed that ten of the genes are predicted to be a target for small molecules. In summary, we identified
previously unknown loci associated with BP. Our findings extend our understanding of genes involved in BP regulation, which may
provide new targets for therapeutic intervention or drug response stratification.Introduction
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twin studies has been estimated to be approximately 50%–
60%3,4 and ~40% in family studies. Several studies have
been performed to elucidate underlying genetic factors
for BP, including genome-wide association studies
(GWASs), meta-analyses, and admixture mapping.5–12
Efforts to dissect the genetic basis for this complex disorder
have proven challenging and currently only a small
portion of the total variation in BP can be explained by
common genetic variants associated signals. Part of this
‘‘missing heritability’’ is likely to be due to as yet unknown
common or low-frequency variants, and a fraction of it
could be identified by increasing sample size. Increased
understanding of the underlying genetics may contribute
to improvement of the treatment to reduce CVD risk.
We conducted an association analysis of BP phenotypes
in 87,736 individuals of European ancestry by using a
gene-centric array with ~50,000 SNPs capturing variation
in ~2,100 genes related to CVD, and we replicate our
findings in 68,368 independent individuals. We also per-
formed extensive bioinformatics analyses to identify regu-
latory regions by using the Encyclopedia of DNA Elements
(ENCODE), eQTL studies, and pathway analyses. Finally,
all previously reported BP-associated loci and the genes
within were annotated for their suitability as drug targets.Material and Methods
Population Characteristics
Phenotype and genotype data from 87,736 individuals of
European ancestry from 36 participating studies were used for
the discovery phase, and an additional 68,368 individuals of
European ancestry, from 19 additional studies, were used in the
replication phase. All individuals in these studies provided
informed consent, and each study was approved by its own local
ethics committee. Descriptions of the participating cohorts are
provided in the original publications.5,8,11,13Phenotypes
Pulse pressure (PP) was defined as systolic blood pressure (SBP)
minus diastolic blood pressure (DBP), and median arterial pressure
(MAP) was defined as 2/3 DBP plus 1/3 SBP. Each cohort provided
regression models for its respective data, adjusted for age, age-
squared, body mass index (BMI), and any study-specific correc-
tions for population substructure (based on principal components
analysis). BP values were adjusted for antihypertensive drug ther-
apy by adding a standard treatment adjustment of 15 mmHg to
the SBP and 10 mmHg to the DBP values of individuals receiving
treatment in the discovery and replication cohorts. These adjust-
ments were implemented prior to the calculation of MAP and PP.Genotyping
A total of 52,029 SNPs were included in the meta-analyses, and all
SNPs were present in at least one of the three iterative versions of
the Illumina HumanCVD BeadChip (also known as the ‘‘Cardio-
chip’’ or the ITMAT-Broad-CARe [IBC] array manufactured by
Illumina)14 used by all discovery cohorts. Several studies that
used this array have already been published for a variety of
phenotypes and disease outcomes, including coronary arteryThe Amedisease,16,17 plasma lipids,18 BP,8,11,15 heart failure,19 type 2 dia-
betes (T2D [MIM 125853]),20 and BMI (MIM 606641).21Quality Control, Association, and Meta Analyses
The discovery data sets derive from three BP consortia with
completely independent samples whose results have been pub-
lished separately: the IBC BP consortium8 and the CVD-50
consortium,22 with the addition of the Beaver Dam Studies
(BOSS, EHLS, BDES) consortium.13 The QC steps taken for SNPs
and samples were similar for both consortia, namely: individuals
with <90% call rate (completeness) across all SNPs were removed,
as well as SNPs with<95% call rate (completeness) or SNPs causing
heterozygous haploid genotype calls across all remaining indi-
viduals. SNPs were also removed if they were not in Hardy-
Weinberg equilibrium (p < 1 3 107). No study included imputed
data in their analyses. Further details on genotyping and QC can
be found in the original publications including the BOSS, EHLS,
and BDES studies.8,11,13
During the meta-analysis step, SNPs with frequencies incom-
patible with HapMap CEU frequencies were removed (defined
as >30% difference in the minor allele frequencies) for each data
source separately, i.e., the meta-analysis results of IBC BP, of
CVD-50, and of BOSS, EHLS, and BDES. We used inverse variance
weighted meta-analysis in MANTEL23 to obtain a fixed-effect esti-
mate and statistical significance for each SNP. We applied genomic
control24 to each data set to control effects possibly resulting from
population stratification or cryptic relatedness. The CARe IBC
array studies, included in this meta-analysis, determined that after
accounting for linkage disequilibrium (LD), the effective number
of independent tests was ~20,500 for Europeans. This resulted in
an experimental or ‘‘arraywide’’ statistical threshold of p ¼ 2.4 3
106 to maintain a false-positive rate of 5%25 and therefore we
have adopted this threshold for this study. For each associated
locus, the LD patterns were examined and independence between
the loci identified in this study and previously published signals
was verified with SNAP26 (r2 < 0.3).
Replication analysis was conducted in independent samples for
each trait, for SNPs with association p < 1 3 105 in the discovery
analysis, with a total of 68,368 individuals from the Global Blood
Pressure Genetics (GBPG) consortium,10 Women’s Genome
Health Study (WGHS),27 and PREVEND28 and LifeLines29 studies.
We combined discovery and replication data in a meta-analysis
and accounted for testing four phenotypes (albeit highly cor-
related), resulting in a Bonferroni-corrected threshold of p < 6 3
107 for the combined meta-analysis of discovery and replication
samples.Definition of Associated Gene Variants and Variant
Functional Analysis
The extended locus around each associated SNP was defined by
identification of all SNPs showing r2R 0.5. Linkage disequilibrium
was defined with the HaploReg tool30 based on Phase I of the 1000
Genomes project. Variants showing evidence of LD with associ-
ated variants were explored for impact on gene function via
Annovar31 and regulatory function (including eQTLs) by
HaploReg30 and RegulomeDB,32 which both collate data from
the Encyclopedia of DNA Elements (ENCODE)33 and nine eQTL
studies.32 Associated genes were reviewed for evidence linking
them to BP-related phenotypes via PubMed and ‘‘hypertension,’’
‘‘cardiovascular disease,’’ or ‘‘vascular disease’’ as medical subject
headings (MeSH) terms. MeSH is a controlled vocabulary createdrican Journal of Human Genetics 94, 349–360, March 6, 2014 351
by the National Library of Medicine (NLM) to index journal
articles and books in the life sciences. All articles in MEDLINE
have been annotated with MeSH by NLM curators or designees,
offering a sensitivemeasure of correlation between biological traits
and genes in the literature.34 We also checked for annotation to
the gene ontology term ‘‘regulation of blood pressure,’’ which
also represents a highly curated set of genes consistently linked
to blood pressure.35 At a pathway level, we used GeneGoMetacore
(Thomson Reuters) to construct a custom BP network based on
436 genes annotated to the ‘‘hypertension’’ MeSH term and gene
ontology terms described above. The Metacore database is a
large commercial database of curated human, rat, and mouse
gene and protein interactions individually evidenced in the
literature.36 This allowed us to construct a core network of inter-
acting genes that are each individually linked to blood pressure,
which collectively are likely to represent a significant blood pres-
sure gene network. We used this network as a tool to investigate
direct interactions between the blood pressure gene network and
the genes in the blood pressure loci reported here. By combining
network data with data on gene and variant function, we were
able to prioritize genes based on their level of support with respect
to BP phenotypes.Analysis of Pharmacologic Targets
We annotated genes containing variants in LD (HapMap CEU
r2 > 0.5) with discovered associations and analyzed information
concerning potential druggability—that is, the potential for mod-
ulation of the protein target by a water-soluble small-molecule
drug. Druggable proteins usually contain a defined binding pocket
or active site, which could act as a site of action (pharmacophore)
for an orally bioavailable small-molecule drug. We grouped pro-
teins into four druggability classes, based on complementary
annotations of the potentially druggable genome and publicly
available databases of small molecules. Targets in class 1 are
already drugged with a marketed drug recorded in DrugBank; class
2 have small molecules recorded in ChEMBL, which may include
compounds in current development within pharmaceutical com-
panies, and could be used as tools in animal and cellular models;
class 3 are homologous to class 1 or class 2 targets; and class 4
are predicted to contain a potentially druggable pharmacophore
based on de novo structure-based druggability prediction via the
online available DoGSiteScorer tool,37 which binds site prediction,
analysis, and druggability.Expression Quantitative Trait Loci Analysis
We identified alias identifiers for significant index SNPs by using
SNAP, an online tool for LD calculations.26 Further proxy SNPs
displaying high LD (r2 > 0.8) were identified across four
HapMap builds in European ancestry samples (CEU) with SNAP.
The primary SNPs and LD proxies were searched against a collated
database of expression SNP (eSNP) results including the following
tissues: fresh lymphocytes,38 fresh leukocytes,39 leukocyte samples
in individuals with celiac disease (MIM 212750),24 whole blood
samples,40–43 lymphoblastoid cell lines (LCLs) derived from
asthmatic children (MIM 600807),44,45 HapMap LCLs from three
populations,46 a separate study on HapMap CEU LCLs,47 addi-
tional LCL population samples,48–51 CD19þ B cells,52 primary
PHA-stimulated T cells,48 CD4þ T cells,53 peripheral blood
monocytes,52,54,55 CD11þ dendritic cells before and afterMycobac-
terium tuberculosis infection (MIM 607948),56 omental and subcu-
taneous adipose,40,50,57 stomach,57 endometrial carcinomas (MIM352 The American Journal of Human Genetics 94, 349–360, March 6608089),58 ERþ and ER breast cancer tumor cells (MIM
114480),59 brain cortex,54,60,61 prefrontal cortex,62,63 frontal
cortex,64 temporal cortex,61,64 pons,64 cerebellum,61,64 three addi-
tional large studies of brain regions including prefrontal cortex,
visual cortex, and cerebellum,65 liver,57,66,67 osteoblasts,68
ileum,57,69 lung,70 skin,50,71 and primary fibroblasts.48 MicroRNA
QTLs were also queried for LCLs72 and gluteal and abdominal
adipose.73 The collected eSNP results met the criteria for associa-
tion with gene expression levels as defined in the original papers.
Themajority of eQTLs (15/17) showed a p value of 13 106 or less.
Two replication studies with more modest association were also
included. We placed more value on eQTLs with low p values
that showed consistent reporting across independent studies. In
each case where a SNP or proxy was associated with transcript
levels, we further examined the strongest eSNP for that transcript
within that data set (best eSNP) and the LD between the best eSNP
and BP-selected eSNPs to estimate the concordance of the BP and
expression signals.Results
Discovery Meta-analysis
In the discoverymeta-analysis, four BP traits were analyzed
in 87,736 individuals from 36 cohorts, as described in
Table S1 available online. We analyzed SBP, DBP, MAP,
and PP as continuous traits. Cohort characteristics,
including age, sex, BP values, and the proportion of indi-
viduals treated with BP-loweringmedications, are provided
in Table S1.
Association analyses were successfully carried out for up
to 48,616 SNPs that passed QC. We identified 17 SNPs that
passed a suggestive discovery p value threshold of p < 1 3
105 with six SNPs showing strongest associations with
SBP, i.e., lowest p value among all four traits (and one sec-
ondary association, i.e., a threshold-passing p value but
with a higher p value than in another trait), two SNPs
showing strongest associations with DBP (and two other
secondary associations), two showing strongest associa-
tions with MAP (and two other secondary ones), and
three leading associations to PP (with three secondary
associations).
Replication Analyses
Replication testing was performed in 68,368 additional
individuals from 19 cohorts with genome-wide SNP geno-
types imputed to HapMap, only to the signals passing the
threshold on discovery and previously not published. A
meta-analysis of the 17 SNPs taken forward from the dis-
covery phase with replication data showed that 11 SNPs
at independent loci met our Bonferroni-corrected array-
wide significance threshold of p < 63 107. Some of these
SNPs showed association with more than one trait, which
resulted in 17 previously not described associations: three
loci were associated with DBP (PDE1A [MIM 171890],
HLA-DQB1 [MIM 604305], and VCL [MIM 193065]), five
loci were associated with SBP (PRKAG2 [MIM 602743],
H19 [MIM 103280], NUCB2 [MIM 608020], SIPA1 [MIM
602180], and HOXC complex [MIM 142974]), five loci, 2014
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Figure 1. Overview of the Replicated Blood-Pressure-Related
Findings from This Meta-analysis for Overlap with the Various
Blood-Pressure-Related Traits
Abbreviations are as follows: SBP, systolic blood pressure; DBP,
diastolic blood pressure; MAP, mean arterial pressure; and PP, pulse
pressure.were associated with MAP (PDE1A, VCL, H19, NUCB2, and
RELA [MIM 164014]), and four loci were associated with PP
(CDK6 [MIM 603368], NUCB2, FBN1 [MIM 134797], and
NFAT5 [MIM 604708]) (Figure 1). The association results
are summarized in Table 1. We also found a suggestive as-
sociation in ERAP1 (MIM 606832) with 2.4 3 106 > p >
6 3 107, which reached array-wide significance but not
Bonferroni-corrected significance (array-wide significance
divided by the number of traits, four).
We compared the results of our analysis with all pub-
lished associations at the time of this report (to the best
of our knowledge)5,8–11,22,74–77 and confirmed previously
reported BP associations at 27 loci with same direction of
effect (at a nominal association threshold [p < 0.05]), out
of 32 loci covered by this genotyping array, with partial
sample overlap between original findings and our study
(Table S2 contains all previously reported loci and our p
values for these associations; each column with an X indi-
cates a significant result was found by the referred study to
the specified trait). We did not find supportive evidence of
association with BP of five loci: CACNB2 (MIM 600003),
CDH13 (MIM 601364), C10orf107 (MIM not available),
ZNF652 (MIM 613907), and STK39 (MIM 607648), which
were found in GWAS meta-analyses. The IBC array does
not contain lead SNPs or proxies for 18 of the previously
reported loci identified by GWASs.
eQTLs
Several of the reported loci have significant eQTLs.
rs2854275 is associated with the expression of HLA-DRB4
in monocytes (p ¼ 4.82 3 1095) and in liver (p ¼ 1.31 3
1010) and HLA-DRB1 (MIM 142857) in blood (p ¼The Ame3.203 1059); rs2282978 associates with CDK6 expression
(MIM 603368) (p ¼ 2.63 105); rs4746172 is in perfect LD
with rs10824069, which presents a significant association
with expression of the ADK transcript (MIM 102750) in
lung (p < 2 3 1016); and rs217727 is associated with
increased expression of AK126915 in LCLs (p ¼ 2.40 3
106) and skin (p ¼ 6.59 3 106). Closer investigation of
the AK126915 transcript in the UCSC Genome Browser
suggests that it may represent an isoform of the mitochon-
drial ribosomal protein L23 (MRPL23 [MIM 600789]) (data
not shown). rs757081 is associated with expression of
NUCB2 (MIM 608020) in LCLs in asthmatics (p ¼ 1.56 3
1016) and of SNORD14A in LCLs (p ¼ 3.10 3 105);
rs33063 is associated with expression of another unknown
transcript, LOC283970 in B cells (p ¼ 9.55 3 108); and
rs3741378 is in tight LD with several SNPs that present
significant eQTL levels in lymph, liver, and other tissues.
Table S4 presents the results in more detail.Extended Locus Analysis and Variant Functional
Analysis
Variants in LD (r2 > 0.5) with the 11 replicated SNPs are
functionally annotated in Table S5, and a nonredundant
list of corresponding genes appear in Table S6. Several
loci contained only one gene (PDE1A, HLA-DQB1, CDK6,
PRKAG2, and FBN1), whereas others contained several
genes (see Table S6). By comprehensive functional annota-
tion, we reviewed the genes at each locus both for evidence
of functional impact (genic and regulatory) and a rationale
in BP.Discussion
In this study we identified 11 loci associated with BP traits
(p < 6 3 107) in a meta-analysis comprising 87,736
individuals of European descent. These associations were
validated in a replication cohort of 68,368 individuals.
The robust sample size also confirmed a nominal associa-
tion (p < 0.05) of 27 previously reported signals, out of
the 32 previously reported loci covered by this array.Associated Loci with a Single Candidate Gene
Of the 11 loci described in this study, 5 contain only a
single gene. The PDE1A locus contains the phosphodies-
terase 1A (PDE1A) gene, a Ca2þ/calmodulin-stimulated
phosphodiesterase that preferentially hydrolyzes cGMP
and has an important role in regulating vascular tone
and smooth muscle cell proliferation.78,79 The HLA-
DQB1 locus containsHLA-DQB1 (major histocompatibility
complex, class II, DQ beta 1), which encodes a class II
molecule expressed in antigen-presenting cells and plays
a role in the immune system by presenting peptides
derived from extracellular proteins. HLA-DQB1 alleles
have been linked to essential hypertension in Chinese
populations.80 At the PRKAG2 locus, PRKAG2 (protein
kinase, AMP-activated, gamma 2 noncatalytic subunit) isrican Journal of Human Genetics 94, 349–360, March 6, 2014 353
Table 1. Significant Association Results for All Four Traits in the Meta-analysis
Locus SNP CHR Pos Effect Allele
Discovery p Values Replication p Values Combined Discovery þ Replication
(n ¼ 87,736) (n ¼ 68,368) beta SE p Val
DBP
PDE1A rs16823124 2 182932372 A 1.76 3 106 2.59 3 105 0.262 0.041 1.95 3 1010
HLA-DQB1 rs2854275 6 32736406 A 2.97 3 108 1.86 3 104 0.562 0.101 5.53 3 1012
VCL rs4746172 10 75525848 C 2.14 3 105 1.07 3 103 0.230 0.043 9.14 3 108
MAP
PDE1A rs16823124 2 182932372 A 1.10 3 104 3.85 3 104 0.269 0.052 1.90 3 107
VCL rs4746172 10 75525848 C 7.91 3 106 8.73 3 103 0.279 0.054 2.45 3 107
H19 rs217727 11 1973484 A 1.63 3 105 3.94 3 103 0.315 0.061 2.15 3 107
NUCB2 rs757081 11 17308259 G 3.23 3 105 1.16 3 103 0.265 0.050 1.39 3 107
RELA rs3741378 11 65165513 T 3.08 3 105 2.30 3 103 0.359 0.070 2.44 3 107
PP
CDK6 rs2282978 7 92102346 C 3.82 3 108 0.073 0.268 0.049 4.51 3 108
NUCB2 rs757081 11 17308259 G 4.51 3 107 4.48 3 105 0.321 0.050 8.94 3 1011
FBN1 rs1036477 15 46702218 G 6.59 3 106 8.02 3 103 0.402 0.077 2.00 3 107
NFAT5 rs33063 16 68197718 A 9.07 3 107 0.063 0.335 0.066 4.14 3 107
SBP
PRKAG2 rs10224002 7 151045974 G 1.67 3 106 0.023 0.361 0.072 5.50 3 107
H19 rs217727 11 1973484 A 7.88 3 106 2.95 3 103 0.417 0.078 1.03 3 107
NUCB2 rs757081 11 17308259 G 2.26 3 107 1.28 3 104 0.403 0.063 1.65 3 1010
RELA rs3741378 11 65165513 T 1.70 3 106 4.42 3 105 0.546 0.087 3.41 3 1010
HOXC@ rs7297416 12 52729357 C 2.26 3 106 0.011 0.334 0.065 2.32 3 107important in cellular metabolism and has been associated
with Wolff-Parkinson-White syndrome (MIM 194200),
urate levels and chronic kidney disease,81,82 and accumula-
tion of cardiac glycogen and left ventricular hypertrophy
resembling hypertrophic cardiomyopathy.83,84 Chronic
kidney disease and left ventricular hypertrophy represent
target organ damage related to hypertension, and thus,
our findings may provide a link between genetic loci
affecting BP and the occurrence of clinically important
sequelae. Other traits associated with PRKAG2 include
hemoglobin85 and hematocrits.86 The FBN1 locus encodes
fibrillin-1 (FBN1), a component of elastic fibers in connec-
tive tissue, and this gene has been associated with Marfan
syndrome (MIM 154700), with systolic and pulse pressure,
with aortic stiffness in patients with coronary artery dis-
ease (CAD),87,88 and with thoracic aortic aneurysms and
thoracic aortic dissection.89 CDK6 variants are associated
with height (MIM 606255) in a number of studies90–92
and are implicated in white blood cell counts in Japanese
populations93,94 and in African Americans.95
Associated Loci with Multiple Genes
The remaining loci (VCL, H19, NUCB2, SIPA1, HOXC4,
and NFAT5) contain several genes that we have prioritized354 The American Journal of Human Genetics 94, 349–360, March 6on the basis of variant functionality and the biological
rationale of the genes in the BP phenotypes.
We consider vinculin (VCL) the strongest biological
candidate. Vinculin is a cytoskeletal protein, localized to
intercalated discs, and by anchoring thin filaments it is
implicated in cardiac force generation. Targeted disruption
of vinculin in mice has shown loss of cardiac contractility
in embryonic development.96 The two other candidates at
the VCL locus (AP3M1 and ADK) show moderate evidence
of functional variation.
The H19 locus contains three genes. H19 (H19,
imprinted maternally expressed transcript [nonprotein
coding]) expresses a noncoding RNA. Methylation defects
in this gene have been associated with pre-eclampsia in a
study with 188 pregnancies97 and imprinting syndromes
such as Beckwith-Wiedemann syndrome (MIM 130650)
and growth retardation disorder Silver-Russell syndrome
(MIM 180860).98,99 The locus also contains the mitochon-
drial ribosomal protein L23 (MRPL23) and an antisense
transcript MRPL23-AS1. There are no data suggesting a
putative role in BP for the latter, but eQTL analysis identi-
fied a putative isoform of MRPL23 (AK126915).
The NUCB2 locus contains four genes: PIK3C2A,
NUCB2, NCR3LG1, and KCNJ11. The product of NUCB2,, 2014
nucleobindin 2, induces hypertension when intracere-
brally administered.100 It is also involved in the mainte-
nance of calcium blood levels, feeding behavior, water
intake, glucose homeostasis, and the release of tumor ne-
crosis factor from vascular endothelial cells by interacting
with ERAP1.101,102 It has been also associated with height
in GWASs.90–92 The potassium inwardly rectifying chan-
nel, encoded by KCNJ11, is also a good biological candi-
date, which has been reported to be associated with
hypertension103 as well as type 2 diabetes, although the
previously reported variants are not in LD with the associ-
ation reported in this study.
The SIPA1 locus contains seven genes: MAP3K11,
PCNXL3, SIPA1, RELA, KAT5, RNASEH2C, and AP5B1.
SIPA1 (signal-induced proliferation-associated 1) is the
strongest functional candidate, and the associated SNP
encodes a nonsynonymous p.Ser182Phe polymorphism,
which is predicted to be deleterious by several bioinfor-
matics tools.31 The strongest biological candidate is the
adjacent RELA (a.k.a. NF-kB3), which forms part of the
NF-kB protein complex and has been shown to modulate
angiotensin II-induced hypertension in the paraventri-
cular nucleus.104
The HOXC4 locus contains three homeobox genes:
HOXC4, HOXC5, and HOXC6. All three genes are closely
related and encode transcription factors involved in
morphogenesis. A recent trans-ethnic GWAS on blood
pressure found a signal related to HOXCA,105 suggesting
that homeoboxes may have an association with blood
pressure in more ethnicities.
The NFAT5 locus also contains several candidates,
including NFAT5 (Nuclear factor of activated T cells 5).
NFAT5 is a transcription factor, recently shown to regulate
vascular smooth muscle cell (VSMC) modulation.106
In vivo studies in NFAT5þ/ApoE/ mice indicated that
NFAT5 is directly involved in atherosclerotic lesion forma-
tion and identified NFAT5 as a positive regulator of athero-
sclerotic lesion formation.107 A variant at this locus has
also been associated with serum urate81 and age at
menarche.108 Small-molecule activators of the adjacent
NQO1 (NAD(P)H:quinone oxidoreductase) have been
shown to ameliorate spontaneous hypertension in animal
models via modulation of eNOS activity.109 The Ubiquitin-
protein ligase WWP2 is also a candidate, because it is
known to bind and downregulate the epithelial Na(þ)
channel (ENaC). Mutations in WWP2 have been shown
to result in hypertension.110
Therapeutic Opportunities
Current antihypertensive medications do not show com-
plete efficacy in all subjects and often require combina-
tion therapy of three or more drugs to reach a target
blood pressure, and ~10% of individuals show limited
reduction in blood pressure on all therapeutic regi-
mens.111 This highlights the need for additional antihy-
pertensive medications, both to improve efficacy of
treatment and reduce the burden of side effects experi-The Ameenced, particularly where combination therapies are con-
cerned. Among the associations reported in this manu-
script, there is evidence of association for 15 genes that
are either current drug targets or are potentially druggable
based on the predicted potential of a protein to be modi-
fied by a small-molecule drug in our analyses. Two genes
are targeted by currently widely applied drugs. The
KCNJ11 product is targeted by several agents including
the antihypertensive drug verapamil (DrugBank ID
DB00661) and the glucose-lowering agent glyburide
(DrugBank DB01016). NQO1 is targeted by several
marketed anticoagulant drugs, including dicumarol and
menadione (DrugBank DB00266 and DB00170). The pro-
tein encoded by RELA is part of the NF-kB protein com-
plex, which is considered to be inhibited by several
known drugs, including the antihypertensive olmesartan
(DrugBank DB00275)112 and the alcohol deterrent drug
disulfiram (DrugBank DB00822). A known side effect of
disulfiram in presence of alcohol exposure is hypoten-
sion, which gives support to a potential role of RELA in
hypertension.
Nine genes with evidence of association have also pre-
viously described small-molecule modulators (mainly
inhibitory or binding) based on a query of the ChEMBL
database. The genes are listed with the number of tool
compounds in parentheses: PDE1A (42), CDK6 (405),
ADK (483), MAP3K11 (192), RELA (289), KAT5 (25), and
PIK3C2A (10). The number of molecules identified may
indicate the extent of drug discovery research that has
been focused on each target. Many are likely to be the
focus of pre-existing drug development in industry that
may still be ongoing or terminated.113 Once molecular
properties of these compounds are considered to have a
favorable profile, they could be investigated in animal
models of hypertension; a large number of compounds
have already been characterized: the ChEMBL database
reports that 405 molecules show activity against CDK6.
Most of these CDK6 inhibitors originate from the pub-
lished GSK (Glaxosmithkline) kinase inhibitor set.113 A
review of the molecular properties of these molecules in
ChEMBL shows that they have similar drug-like features
and are likely to be orally bioavailable (based on Lipin-
ski’s rule of five compliance114). As we described earlier,
association is limited to CDK6 only, and because many
of these drug-like molecules would be suitable for imme-
diate evaluation in animal models of hypertension,
this might be a worthwhile experiment, even in the
absence of other strong evidence to support the role of
CDK6 in BP.
The 11 loci identified in the present study increase our
knowledge on BP-related processes and shed light on
plausible candidates at each locus and networks, via
eQTL and pathway analysis. It is particularly interesting
that most of the genes within the associations are suitable
candidates for existing drugs or preclinical compounds.
These new observations will help to improve our knowl-
edge on BP and related mechanisms.rican Journal of Human Genetics 94, 349–360, March 6, 2014 355
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